NICE has approved the use of exenatide in triple therapy regimens for patients with type 2 diabetes, in latest guidance. Patients should be offered the drug if they are struggling to control their blood glucose levels or if they remain inadequate.
Green light for earlier use of rheumatoid arthritis drug
Patients with rheumatoid arthritis can now be offered tocilizumab alongside other treatment options at an earlier stage. The drug is recommended, in combination with methotrexate, for treating rheumatoid arthritis if treatment with disease-modifying anti-rheumatic drugs (DMARDS) has failed.
Improving access to NICE-approved drugs
NICE is to produce a best practice guide to help trusts develop local formularies, as part of a move to ensure that all patients in England have access to clinically and cost-effective drugs. This comes as latest findings reveal that not all local formularies are including all of NICE's technology appraisals.
Making sure pregnant and breastfeeding women receive vitamin D
Certain groups of people are at particular risk of vitamin D deficiency, such as pregnant women and those who breastfeed. NICE has recognised this and produced public health guidance on maternal and child nutrition which recommends the use of vitamin D supplements to ensure they are getting all the nutrients they need.
Clinical case scenarios
NICE has developed a number of new clinical case scenarios to help improve and assess users' knowledge of our guidance. The case scenarios are an excellent educational resource that can be used for individual or group learning. This month, we have case scenarios covering our guidance on adult and paediatric epilepsy, self harm and colorectal cancer.
Let us know what you think about the draft recommendations for a clincial guideline on neutropenic sepsis - a potentially fatal complication of anti-cancer treatments such as chemotherapy. The guideline covers the prevention, identification and management of the complication.
Should our public health guidance on needle and syringe programmes be updated? NICE reviews all public health guidance after 3 years to see whether the evidence base has moved on. Have your say on whether the guidance needs to incorporate new evidence.